FDA Approves First Oral Prophylactic for COVID-19 Prevention
On October 13, 2026, the U.S. FDA approved Shionogi’s Xocova (ensitrelvir), marking the first oral medication for COVID-19 post-exposure prophylaxis in adults and adolescents aged 12 and older. The approval is based on a Phase III trial demonstrating a 67% reduction in symptomatic COVID-19 risk.
On October 13, 2026, the FDA granted approval for Shionogi’s Xocova (ensitrelvir), making it the first oral medication authorized for post-exposure prevention of COVID-19 in adults and adolescents aged 12 years and older. This decision marks a significant shift in how the virus is managed, expanding the role of antiviral therapies from active treatment to include preventive care. The approval was issued in advance of the drug’s Prescription Drug User Fee Act action date, which had been set for June 16, 2026.
The authorization is supported by data from the Phase III Scorpio-Pep trial, the first oral antiviral study to meet its primary goal of preventing symptomatic COVID-19 after exposure. Researchers found that Xocova reduced the risk of developing symptoms by 67% through Day 10 when compared to a placebo. These results were observed in participants who had been in close contact with an infected person but were not infected themselves at the start of the study, highlighting the drug's potential as a public health tool.
Patients prescribed Xocova follow a five-day oral regimen, taking three tablets on the first day and one tablet daily for the remaining four days. During clinical trials, the medication showed a safety profile comparable to the placebo group, with adverse events reported at 15.1% for the treatment group and 15.5% for the placebo group. The most frequent reactions included headache, diarrhea, and cough; notably, no participants reported cases of treatment-related dysgeusia.
The approval of Xocova introduces a new prevention strategy as the focus moves toward the long-term management of SARS-CoV-2. According to CDC estimates, there were between 3.8 million and 12.4 million COVID-19 cases in the United States between October 2025 and May 2026, resulting in a high number of hospitalizations and deaths. By providing a new option for those at risk of exposure, Xocova may help reduce the overall burden on the healthcare system.
Looking ahead, the introduction of Xocova opens further avenues for research into antiviral therapies. Future milestones will likely involve assessing its effectiveness across various populations and settings, as well as exploring its use in combination with other COVID-19 treatments. This approval represents a transition in the ongoing response to the virus, providing a new tool for prevention and public health outcomes.
Enjoyed this story?
Show the newsroom a little love — one tap per reader.
Priya reports on breakthroughs that change lives, big and small.
Be part of the good
Stories like this start with people who care. Share it, or submit your own uplifting story to inspire millions today.
